Biotech startup Delix Therapeutics has unveiled promising interim phase 1 safety data for its lead neuroplasticity drug candidate DLX-001 at a leading neuroscience conference, marking the first clinical validation of its “psychoplastogen” pipeline. In essence, the company is developing psychedelic-inspired therapies that can prompt neuroplasticity without the hallucinogenic, psychotomimetic, or dissociative effects typical with traditional psychedelic compounds.
According to Delix’s chief medical officer Dr. Aaron Koenig, DLX-001 is safe and well-tolerated. With neuroplasticity emerging as a key factor in rapid-acting antidepressant mechanisms, the company is optimistic about this early human proof-of-concept, which could pave the way for larger efficacy studies and offer an alternative approach in the field where psychedelic medicines have shown limitations, particularly in terms of side effects and potential cardiac liability.
The interim data fro…